We observed that 11.3% of male severe COVID-19 patients (9/80 individuals, 15 samples) and 13.0% of female severe COVID-19 patients (3/23 individuals, 8 samples) had clearly detectable IgG autoantibodies targeting IFNα2 in their plasma, which were not present in the plasma of 130 healthy donors (Fig 1A). This evidence concerns the gene IFNA2 and COVID-19.